O-GlcNAcylation (O-linked β-N-acetylglucosaminylation) is notably decreased in Alzheimer’s disease (AD) brain. Necroptosis is activated in AD brain and is positively correlated with neuroinflammation and tau pathology. However, the links among altered O-GlcNAcylation, β-amyloid (Aβ) accumulation, and necroptosis are unclear. Here, we found that O-GlcNAcylation plays a protective role in AD by inhibiting necroptosis. Necroptosis was increased in AD patients and AD mouse model compared with controls; however, decreased necroptosis due to O-GlcNAcylation of RIPK3 (receptor-interacting serine/threonine protein kinase 3) was observed in 5xFAD mice with insufficient O-linked β-N-acetylglucosaminase. O-GlcNAcylation of RIPK3 suppresses phosphorylation of RIPK3 and its interaction with RIPK1. Moreover, increased O-GlcNAcylation ameliorated AD pathology, including Aβ burden, neuronal loss, neuroinflammation, and damaged mitochondria and recovered the M2 phenotype and phagocytic activity of microglia. Thus, our data establish the influence of O-GlcNAcylation on Aβ accumulation and neurodegeneration, suggesting O-GlcNAcylation–based treatments as potential interventions for AD.
Read full text: O-GlcNAcylation ameliorates the pathological manifestations of Alzheimer’s disease by inhibiting necroptosis. By JINSU PARK, HEE-JIN HA, EUN SEON CHUNG, SEUNG HYUN BAEK, YOONSUK CHO, HARK KYUN KIM, JIHOON HAN, JAE HOON SUL, JEONGMI LEE, EUNAE KIM, JUNSIK KIM, YONG RYOUL YANG, MIKYOUNG PARK, SUNG HYUN KIM, THIRUMA V. ARUMUGAM, HYEMIN JANG, SANG WON SEO, PANN-GHILL SUH, DONG-GYU JO. SCIENCE ADVANCES, 13 JAN 2021 : EABD3207
O-GlcNAcylation ameliorates the pathological manifestations of Alzheimer’s disease by inhibiting necroptosis https://t.co/0DTjnC2vII #Alzheimers #Necroptosis @erlesen @HealthyFellow @MarcoAlbuja @ShraboniGhosal
More from #DHPSP, INPST, and CRBIOTECH: https://t.co/1R2kSL54sX pic.twitter.com/qsWKniBXEM
— Science Communication (@ScienceCommuni2) January 24, 2021